Oncolytics Biotech’s (ONCY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a report released on Thursday morning,Benzinga reports. They currently have a $5.00 price target on the stock.

Oncolytics Biotech Trading Down 3.0 %

NASDAQ ONCY opened at $0.98 on Thursday. The company has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.06. Oncolytics Biotech has a 12-month low of $0.84 and a 12-month high of $1.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.